A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Warm Antibody Autoimmune Hemolytic Anemia Clinical Trial

Official title:
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Status Enrolling by invitation

Clinical Trial Summary

The primary objective of this study is: • To evaluate the long-term safety of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Anemia
Anemia, Hemolytic
Anemia, Hemolytic, Autoimmune
Hemolysis
Warm Antibody Autoimmune Hemolytic Anemia

Clinical Trial Details

NCT number	NCT04138927
Study type	Interventional
Source	Rigel Pharmaceuticals
Contact
Status	Enrolling by invitation
Phase	Phase 3
Start date	October 30, 2019
Completion date	April 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05535933` - HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia	Phase 2/Phase 3
Active, not recruiting	`NCT04657094` - Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia	Phase 2
Completed	`NCT02612558` - A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)	Phase 2
Completed	`NCT03764618` - A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA	Phase 3